Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis

Chen, David Qixiang, Inzunza Domínguez, José Adalberto, Valle Uzeta, Juan Manuel, Pushparaj, Abhiram P., Dickinson, Jonathan E. · 2025 · Frontiers in Immunology

AI-extracted · unverified · confirm at source

Two MS patients showed lesion shrinkage and decreased ADC values on MRI after ibogaine, suggesting remyelination. Cortical/subcortical changes in pain/emotion regions. First neuroimaging evidence for ibogaine in MS.

Dosing: 500–1200 mg ibogaine HCl flood dose; 20 mg/day maintenance microdose (oral)

Sample size: 2

Safety data present: ELECTROLYTE